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Recent  studies  have  shown that vitamin Be modulates 
transcriptional  activation by the human  glucocorticoid 
receptor  in  HeLa S3 cells. We have now  examined  the 
possibility that vitamin Be might  similarly  influence 
transcriptional  activation by the glucocorticoid  recep- 
tor in other cell types, as well as gene expression 
mediated by other members of the steroid hormone 
receptor  superfamily. We show that  elevated  vitamin 
Be concentrations suppress by 40-65’70 the level of 
transcription  mediated  through  the  endogenous  murine 
L cell glucocorticoid receptor, as well as the human 
receptor  transfected  into E8.2 and  T47D cells. In con- 
trast, glucocorticoid receptor-mediated transcription 
was enhanced 60-110% in mild vitamin deficiency. 
The level of hormone-independent constitutive gene 
expression  was  not  affected  by  these  same  alterations 
in vitamin B e  concentration.  These  studies  indicated 
that  the  transcriptional  modulatory  effects of the  vi- 
tamin  were  neither  restricted  to specific  cell types  nor 
limited  to  the  human  form of the glucocorticoid  recep- 
tor. We next  determined if hormone-induced  transcrip- 
tion by several  other  steroid  receptors  (androgen,  pro- 
gesterone, and estrogen receptors) was analogously 
affected by alterations in vitamin Be concentration. 
Analysis of gene expression mediated through the 
mouse mammary  tumor  virus  promoter  revealed  that 
transcriptional activation of both the androgen and 
progesterone  receptors  was  reduced  by 35-40% under 
conditions of elevated  vitamin Be and  enhanced by 60- 
90% in deficiency, again  under  conditions  where con- 
stitutive  expression  was  unaffected.  Using a different 
promoter,  the  estrogen-regulated  vitellogenin  pro- 
moter, we  found that  transcriptional  activation of the 
estrogen  receptor  was  simlarly  affected.  Estrogen-in- 
duced  gene  expression  was  reduced by 30% under con- 
ditions of elevated intracellular vitamin Be and en- 
hanced  by 85% in  vitamin deficiency.  Thus, vitamin 
Be modulates transcriptional activation by multiple 
classes of steroid  hormone  receptors.  The  similarities 
in vitamin Be effects  on  transcription  mediated 
through  different  promoters,  the mouse mammary  tu- 
mor  virus  and  vitellogenin  promoters,  suggest  that  this 
vitamin may  modulate the expression of a diverse ar- 
ray of hormonally responsive genes. These observa- 
tions  together  support  the  hypothesis  that  vitamin Be 
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represents a physiological modulator of steroid  hor- 
mone action. 
The  steroid  hormone  receptors belong to a  superfamily of 
transcription  factors  that regulate the expression of specific 
target genes, and, in so doing,  have profound effects on  many 
physiological processes, including growth, development, ho- 
meostasis, reproduction,  and behavior (1). Despite  the diverse 
array of physiological events  modulated by different members 
of this superfamily, receptors  for  the  steroid  hormones glu- 
cocorticoid, estrogen,  androgen,  and progesterone exhibit 
many structural and functional similarities. For example, 
early  studies employing limited proteolytic  digestion of steroid 
receptor preparations  first suggested that  these molecules are 
structurally  similar  (2);  subsequent  cDNA cloning and  DNA 
sequence analysis  has  demonstrated  not only that  the  steroid 
hormone receptors share a common modular organizalion, 
with specific domains encompassing the ligand and DNA- 
binding  domains,  but  also  that considerable  sequence  homol- 
ogy exists  among  the receptor molecules (3-6). These recep- 
tors  are also functionally analogous in  mediating  their biolog- 
ical effects, and  they  all proceed through common mechanistic 
steps, including binding of steroid ligand,  recognition of spe- 
cific DNA sequences, and  modulation of target gene expres- 
sion (5, 7-9). 
The capacity of target cells or  tissues  to  respond  to  hor- 
monal stimulation is influenced by a variety of conditions, 
including the  intracellular  concentration of receptors (10, l l ) ,  
the  state of differentiation  or development of the cell or  tissue 
(12, 13),  and  the  stage of the cell cycle (14). Hormone respon- 
siveness can  also be affected by other  factors, for example, 
serum  components (15), mitogenic agents (16), intracellular 
second  messengers (15, 17), and  nutritional compounds, such 
as  butyric  acid (18-20) and  the  vitamin A  derivative  retinoic 
acid (21-23). In  addition,  data from  several laboratories  has 
suggested that another nutritional compound, vitamin Bs, 
may influence steroid  hormone  action.  In  early  studies with 
the  progesterone  receptor,  pyridoxal-5’-phosphate,  the  phys- 
iologically active  form of vitamin Bs, was  observed to  inhibit 
the interaction of this receptor with ATP-Sepharose (24). 
With  the  caveat  that  binding  to  ATP-Sepharose only mimics 
binding to  DNA,  this provocative observation  first suggested 
a link between vitamin Bs and steroid hormone receptors. 
Subsequent  studies  with  the progesterone, estrogen, androgen, 
and glucocorticoid receptors demonstrated that pyridoxal 
phosphate influences not only the in vitro DNA binding 
capacity (25-29), but also other common properties of steroid 
hormone  receptors, including  molecular conformation or sub- 
unit complexity  (26, 27, 30) and subcellular  localization (31- 
35). While  these effects  suggested that  this  vitamin influences 
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the  structure  and  function of steroid  hormone receptors, it 
was not  clear if these effects were representative of in vivo 
physiological actions of the  vitamin. 
Recent work from our laboratory has demonstrated that 
the primary biological manifestation of glucocorticoid hor- 
mone action, the regulation of target gene expression, is 
affected by modulation of intracellular pyridoxal phosphate 
concentration (36). Specifically, the level of glucocorticoid- 
induced receptor-mediated gene expression is reduced under 
conditions of vitamin elevation, and  enhanced  in mild vitamin 
deficiency, indicating  that  vitamin Bs acts physiologically to 
modulate glucocorticoid hormone  action.  The  structural  and 
functional  similarities between the glucocorticoid and  other 
steroid hormone  receptors, together with the  earlier  reports 
of analogous  effects of vitamin Bs on  other  steroid  hormone 
receptors, suggested that  the  vitamin may modulate  transcrip- 
tional  activation by other  steroid  hormone receptors. We have 
therefore examined the effect of pyridoxal phosphate  on  the 
regulation of target gene expression by the  estrogen,  androgen, 
and progesterone  receptors. Results from these  investigations 
demonstrated  that  alterations  in pyridoxal phosphate  concen- 
tration influence the  capacity of these  different  receptors  to 
induce  expression of target genes under physiological condi- 
tions.  In  addition,  data  presented  here show that  the modu- 
latory effects of the  vitamin  on  transcriptional  activation by 
the glucocorticoid receptor are  not  limited  to  the  human form 
of the glucocorticoid receptor, nor  are  the  modulatory effects 
mediated  through a factor  restricted  to a specific cell type. 
These  observations  together  support  the  hypothesis  that  pyr- 
idoxal phosphate acts specifically to regulate the biological 
activity of several  members of the  steroid receptor superfam- 
ily. We propose that  vitamin Bs is a physiological modulator 
of steroid hormone action. 
MATERIALS AND  METHODS 
Reagents-Acetyl coenzyme  A was from  Pharmacia  LKB Biotech- 
nology. Pyridoxine,  4-deoxypyridoxine, and  glutamine were from 
Sigma. Dexamethasone, progesterone, and 17P-estradiol were from 
Steraloids. R1881 and ['4C]chloramphenicol (40-60 mCi/mmol) were 
from  DuPont-New  England Nuclear. Other  reagents were from  Fisher 
Scientific. 
Recombinant Plasmids-Plasmid pGMCS (37, 38),  containing  the 
chloramphenicol acetyltransferase (CAT)' coding sequence down- 
stream of the mouse mammary  tumor  virus  (MMTV)  promoter  and 
glucocorticoid  regulatory elements, was  provided  by Drs. Roger  Mies- 
feld and Keith Yamamoto (UCSF). pBLCAT2 (39), obtained from 
Drs. Bruno Luckow and  Gunther  Schutz  (Institute for Tumor  and 
Cell Biology, Heidelberg, Germany),  contains  the  thymidine  kinase 
promoter  driving expression of the  CAT coding  sequence. pHEO  (40), 
the  human estrogen  receptor  expression  vector,  was  provided  by Dr. 
Pierre  Chambon  (Institut de  Chimie  Biologique). The  human gluco- 
corticoid receptor expression vector pRShGR  (41) was provided by 
Dr. Ronald  Evans  (Salk  Institute). The estrogen-responsive  reporter 
plasmid  pERENFlCAT was constructed by inserting  the -331/-87- 
base  pair  fragment from the vitellogenin A2 gene promoter  (42)  and 
a n  oligonucleotide comprising a binding site for the transcription 
factor  NF1 (derived  from the  MMTV  long  terminal  repeat sequence 
(43))  into  the vector pElbCAT (44); pElbCAT,  the gift of Dr.  James 
Lillie (Harvard  University),  contains an oligonucleotide bearing  the 
adenovirus E l b  TATA sequence upstream of the CAT coding se- 
quence. 
Cell Culture-HeLa S, cells were grown as monolayer cultures  as 
previously described (36). E8.2 cells (45), the generous gift of Dr. 
Paul Housley (University of South Carolina Medical School), were 
cultured  in Dulbecco's modified essential medium supplemented  with 
3% calf serum  and 2 mM glutamine.  T47D cells (46),  kindly provided 
by Drs. Kathryn Horwitz (University of Colorado Health Sciences 
Center) and Mark Graham (University of North Carolina, Chapel 
Hill), were cultured in Eagle's minimal essential medium supple- 
' The  abbreviations used are: CAT, chloramphenicol acetyltrans- 
ferase; MMTV, mouse mammary  tumor virus. 
mented  with 5% fetal calf serum, 5 ng/ml insulin,  and 2 mM gluta- 
mine. Murine L929 fibroblasts (47),  generously  provided  by Dr. 
Daniel Linzer (Northwestern University), were cultured in Eagle's 
minimal  essential medium supplemented  with  10% calf serum  and 2 
mM glutamine.  Pyridoxine  and 4-deoxypyridoxine were dissolved in 
water and diluted into the culture media to the indicated final 
concentrations.  Dexamethasone was dissolved in  water; progesterone, 
17P-estradiol, and R1881 were dissolved in ethanol. Steroids were 
added to  culture media at  the  concentrations  indicated  in  the figure 
legends. 
Cell Transfections-HeLa  cells were transfected by calcium phos- 
phate  precipitation  as previously  described (36), using 5 pg of CAT 
reporter plasmid per 100-mm culture dish. For estrogen receptor 
studies, HeLa cells were co-transfected with 10 pg of pHEO/dish. 
The E8.2, T47D,  and L cells were identically transfected using 5 pg 
of CAT  reporter plasmid/100-mm dish.  Where  indicated, E8.2 and 
T47D cells were co-transfected  with 0.5 pg of pRShGR/lOO-mm dish. 
Sixteen  hours  after  transfection,  the cell culture media were supple- 
mented  with pyridoxine,  4-deoxypyridoxine, or vehicle (H20) to mod- 
ulate  intracellular pyridoxal phosphate  concentration. After incuba- 
tion for 48 h under these conditions, cells were exposed to the 
appropriate  hormone  under  conditions described in  the figure legends 
prior t,o determination of CAT activity. 
Determination of CAT Actiuity-CAT activity from transfected 
HeLa cells was determined  as previously  described (36), using 500 pg 
of cell extract/reaction.  CAT  activity from transfected E8.2 cells was 
identically determined, using 200 pg of cell extract  in a 5-h react,ion. 
Transfected  T47D cells were analyzed  for CAT  activity with 300 pg 
of cell extract  in a 6-h reaction. CAT activity  from transfected L  cells 
was determined  with 100 pg of cell extract  in a 2-h reaction. CAT 
activity was quantitated by excising the  appropriate  area from the 
thin layer chromatography  plate  and  quantitating I4C by scintillation 
counting;  the  portion of total  ['4C]chloramphenicol converted to  an 
acetylated  form  is  representative of the level of induced CAT activity. 
The level of CAT  activity  measured  in  hormone-treated cells grown 
in the control or unaltered medium is assigned a value of 1.0; the 
amount of CAT  activity measured in  hormone-treated cells grown in 
the  presence of either pyridoxine or 4-deoxypyridoxine is expressed 
as a fraction of the amount of CAT activity from cells grown in 
unaltered medium, i.e. as a fraction of 1.0. For  experiments  in which 
multiple cell types were used, CAT activity is determined and ex- 
pressed for each individual cell type  and  comparisons  are  not made 
across different cell types. The level of CAT activity detected in 
hormone-free cells was barely detectable (less than 1% conversion) 
and  not influenced by different  vitamin  states;  thus,  these values are 
not shown in  the figures. 
RESULTS 
We previously demonstrated  that  the  capacity of the  en- 
dogenous human glucocorticoid receptor in  HeLa SB cells to 
mediate gene expression through  the glucocorticoid-respon- 
sive MMTV  promoter  is affected by intracellular pyridoxal 
phosphate concentration (36). Specifically, supplementation 
of the culture medium with pyridoxine, which we (36)  and 
others (32, 33, 48-50) have  shown  elevates intracellular  pyri- 
doxal phosphate  concentration,  results  in  suppression of glu- 
cocorticoid receptor-induced gene expression. In contrast, 
modest intracellular pyridoxal phosphate deficiency, achieved 
by treatment of cells  with the pyridoxal phosphate  synthesis 
inhibitor 4-deoxypyridoxine (51), produces an  enhancement 
in  the level of receptor-induced  target gene expression. These 
effects are observed under conditions where glucocorticoid 
receptor  number  and ligand binding  capacity  are  not affected, 
and  the level of glucocorticoid-independent constitutive gene 
expression is  unaltered  (36).  To  determine if the modulation 
of glucocorticoid-stimulated gene expression by intracellular 
pyridoxal phosphate  concentration is restricted  to  the  human 
form of glucocorticoid receptor, we examined  the effects of 
pyridoxine or 4-deoxypyridoxine supplementation on the 
capacity of the murine glucocorticoid receptor to induce 
target gene expression. For these studies, we used murine 
L929 fibroblasts transfected with the  MMTV-driven gluco- 
corticoid-responsive  CAT  reporter  vector  pGMCS (37,  38). 
Vitamin B6 and Steroid Hormone  Action 3821 
In parallel transfections, cells were transfected with the 
hormone-independent constitutive CAT reporter vector 
pBLCATX (39) in  order to distinguish between  specific  effects 
of intracellular pyridoxal phosphate concentration on the 
glucocorticoid receptor and  potential effects of the  vitamin 
on other transcription factors involved in induction of re- 
porter gene expression. Results of these  studies  are  presented 
in Fig. 1. As described above, transcriptional activation by 
the endogenous human glucocorticoid receptor in  HeLa cells 
was  modulated by alterations  in  intracellular pyridoxal phos- 
phate concentration, with a 45% decrease in the level of 
receptor-induced gene expression under  conditions of elevated 
vitamin  concentration,  and  an  approximate 2-fold increase 
in  the  opposite  state of vitamin deficiency. Constitutive  ex- 
pression from the glucocorticoid nonresponsive plasmid 
pBLCAT2 was unaffected by alterations  in pyridoxal phos- 
phate  concentration. 
The  data shown in  the  right  portion of the Figure demon- 
strate  that  transcriptional  activation by the endogenous mu- 
rine glucocorticoid receptor in L cells was similarly modu- 
lated, with a 66% decrease in  the level of receptor-induced 
CAT activity in the presence of pyridoxine and a 2-fold 
increase  after exposure to  the  synthesis  inhibitor 4-deoxypyr- 
idoxine. As shown in  the lower portion of the Figure, these 
effects were observed under  conditions  in which glucocorti- 
coid-independent  constitutive gene expression remained  un- 
affected. Thus, modulation of glucocorticoid receptor-me- 
diated gene expression by pyridoxal phosphate  concentration 
was neither  restricted  to  the  human form of the glucocorticoid 
receptor  nor  limited  to  HeLa cells. 
These  observations suggested that  transcriptional  modula- 
tion by vitamin B6 may be a  general property of glucocorticoid 
receptor-mediated gene expression, and we next wished to 
examine  this possibility. Many  properties of transfected glu- 
cocorticoid  receptor,  including nuclear  translocation  and  sub- 
cellular localization, specific DNA binding, transcriptional 
activation,  and ligand-induced  down-regulation are  identical 
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FIG. 1. Vitamin  Be similarly influences the transcriptional 
activation capacity of both the human and murine glucocor- 
ticoid receptors. Left, HeLa cells were transfected with either 
pCMCS ( A )  or pBLCAT2 ( B ) ,  then  cultured  in  unaltered medium 
(CON) ,  medium supplemented with 1 mM pyridoxine (PYR) ,  or 
medium  supplemented with 5 mM 4-deoxypyridoxine ( I D X Y )  prior 
to an  8-h exposure to 100 nM dexamethasone  or vehicle.  Cells trans- 
fected  with  pBLCAT2 were exposed to vehicle only. Right, murine 
L929 fibroblasts (L cells) were transfected with either  pGMCS (C) 
or pBLCAT2 ( D )  and  treated  as above, with 2 mM pyridoxine or 1 
mM 4-deoxypyridoxine. Determination  and  quantitation of CAT  ac- 
tivity was as described under “Materials and Methods.” The data 
shown are representative of a t  least three individual transfection 
experiments. 
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FIG. 2. Vitamin B, influences the transcriptional activation 
capacity of the glucocorticoid receptor expressed in heterol- 
ogous cell types. Left, E8.2 cells were transfected  with  either 
pGMCS  and  pRShGR ( A )  or  pBLCAT2 ( B ) .  After transfection, cells 
were cultured in unaltered medium (CON),  medium supplemented 
with 2 mM pyridoxine (PYR) ,  or medium supplemented with 3 mM 
4-deoxypyridoxine (4DXY)  for 48 h  prior to  an  8-h exposure to 100 
@M dexamethasone or vehicle. Right, T47D cells were transfected 
with  either  pGMCS  and  pRShGR ( A )  or  pBLCAT2 ( B ) ,  then  treated 
as described  above, with 3 mM pyridoxine or 2 mM 4-deoxypyridoxine. 
Determination and quantitation of CAT activity was as described 
under  “Materials  and Methods.” The  data shown are  representative 
of a t  least  three individual transfection  experiments. 
to those of the endogenous receptor (10, 52-58), and it is 
generally  held that effects detected with transfected  receptors 
are reflective of events which  occur with  the endogenous  ones. 
Thus, we examined the effect of altered vitamin status on 
transcriptional  activation by the glucocorticoid receptor 
transfected  into two different cell lines, E8.2 and  T47D cells. 
E8.2 cells are derived from the  murine L929 fibroblast line 
and  are devoid of glucocorticoid receptors (45). The  T47D cell 
line is derived from a human breast cancer, and contains 
insufficient levels of glucocorticoid receptors  to induce gene 
expression in  response  to  dexamethasone  treatment.’ How- 
ever, both of these cell types express functional receptors 
following transfection  with a glucocorticoid receptor expres- 
sion vector (45).* After  co-transfection  with  both  the gluco- 
corticoid-responsive CAT  reporter plasmid pGMCS  and  the 
human glucocorticoid receptor expression vector pRShGR, 
the cells were cultured in the presence of pyridoxine or 4- 
deoxypyridoxine, to elevate or reduce,  respectively, intracel- 
lular pyridoxal phosphate  concentration,  prior  to  stimulation 
with dexamethasone.  The  results from these  studies, shown 
in Fig. 2, demonstrated that transcriptional activation me- 
diated by the glucocorticoid receptor expressed in  these dif- 
ferent cell types was reduced under conditions of elevated 
intracellular  vitamin  concentration, with  a 50% decrease  ob- 
served in E8.2 cells and a 40% decrease measured in  T47D 
cells. In  contrast,  under  the opposite state of vitamin defi- 
ciency, the level of gIucocorticoid receptor-induced gene 
expression was enhanced by approximately 60% in  each cell 
type. As shown in  the lower panels, glucocorticoid-independ- 
ent  constitutive expression remained unaffected under  these 
conditions of altered  vitamin  concentrations.  Thus,  the mod- 
ulatory effect of pyridoxal phosphate  on  transcriptional  acti- 
vation by the glucocorticoid receptor was neither mediated 
through a factor  restricted  to a specific cell type, nor  limited 
to  the endogenously  expressed  receptor. 
V. E. Allgood, unpublished  data. 
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The results in Figs. 1 and 2 clearly demonstrate that  the 
biological function of the glucocorticoid receptor, transcrip- 
tional  activation, was affected by vitamin B6 concentration. 
Since there is direct evidence that vitamin Bs has similar 
effects on several physical and structural properties of the 
glucocorticoid and  other hormone receptors (reviewed in Refs. 
59 and 60), and since a high degree of sequence homology 
exists among the receptors (61), we next sought to determine 
if exposure to agents which alter intracellular pyridoxal phos- 
phate concentration might affect transcriptional activation 
by other steroid hormone receptors in  a manner analogous to 
that which we have seen with the glucocorticoid receptor. We 
first examined the effect of pyridoxine and 4-deoxypyridoxine 
supplementation on induction of reporter gene expression by 
the androgen and progesterone receptors. Extensive charac- 
terization of DNA binding and  transcriptional activation has 
demonstrated that  the glucocorticoid, androgen, and proges- 
terone receptors can act  through the same hormone response 
element to mediate transcription of target genes (62, 62). In 
fact, these three receptors can each bind to and activate 
transcription from the hormone response element present in 
the MMTV promoter, first identified as being responsive to 
the glucocorticoid receptor (64). Therefore, we have utilized 
the same MMTV-driven glucocorticoid-responsive plasmid 
pGMCS for analysis of transcriptional activation by these 
three different receptors. Use of this common reporter plas- 
mid, however, necessitated the use of cells which expressed 
each receptor individually in order to unequivocally establish 
effects of pyridoxal phosphate on induction of transcription 
specifically by the androgen or progesterone receptors. Thus, 
we used  E8.2  cells,  which contain endogenous androgen recep- 
tors hut neither glucocorticoid nor progesterone receptors 
(45), to allow investigation of vitamin effects on the androgen 
receptor. In companion studies, we used T47D cells to exam- 
ine  transcriptional activation by the progesterone receptor; 
these cells express significant levels of progesterone receptors 
(46)  but  contain insufficient levels of either glucocorticoid or 
androgen receptors to activate transcription from a trans- 
fected MMTV-driven CAT reporter construct.* Both cell 
types were transfected with the MMTV-driven CAT reporter 
vector pGMCS, and exposed to  the same pyridoxine or 4- 
deoxypyridoxine conditions demonstrated in Fig. 2 to modu- 
late glucocorticoid receptor-mediated transcriptional activa- 
tion but not hormone-independent constitutive expression. 
After subsequent treatment with the appropriate hormone, 
induction of CAT  gene expression was determined. Results of 
these experiments are presented in Fig. 3. It is  apparent  that 
under the same vitamin conditions which resulted in modu- 
lation of transcriptional activation by the glucocorticoid 
receptor, both androgen receptor-mediated and progesterone 
receptor-mediated gene expression were analogously affected. 
The level of androgen receptor-mediated gene expression was 
suppressed by 28% following pyridoxine treatment,  and  en- 
hanced by 57% after exposure to  the synthesis  inhibitor 4- 
deoxypyridoxine. Similarly, progesterone receptor-mediated 
gene expression was reduced by 41% following exposure to 
pyridoxine, and increased by 90% after growth in media 
supplemented with 4-deoxypyridoxine. The magnitude of 
these effects were quantitatively similar to those observed 
with both endogenous and  transfected glucocorticoid recep- 
tors (Figs. 1 and 2). Thus,  the effects of pyridoxal phosphate 
on steroid receptor-mediated transcriptional  activation were 
not restricted to the glucocorticoid receptor, but extended to 
other members of the steroid hormone receptor family, in- 
cluding at least the androgen and progesterone receptors. 
Because the glucocorticoid, progesterone, and androgen 
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FIG. 3. Vitamin Be influences transcriptional activation of 
the androgen and progesterone receptors. Left, 16 h after  trans- 
fection with pGMCS, E8.2 cells were cultured for 48 h in control 
medium (CON),  medium supplementedwith 2 mM pyridoxine (PYR),  
or medium supplemented with 3 mM 4-deoxypyridoxine ( 4 D X Y ) .  
Cells were then  treated  with  10 nM R1881 or vehicle for 1 2  h prior  to 
CAT  activity  determination. Right, 16  h after  transfection  with 
pGMCS, T47D cells were cultured for 48 h in control medium, 
medium supplemented with 3 mM pyridoxine, or medium supple- 
mented  with 2 mM 4-deoxypyridoxine prior  to a  24-h treatment  with 
1 nM progesterone or vehicle and  CAT  activity  determination.  The 
data  shown are representative of at  least  three individual experiments. 
receptors activate  transcription  as  a  result of interaction with 
the same DNA sequence (62, 63), these studies did not elim- 
inate the possibility that  the effects of vitamin B6 might be 
restricted to specific MMTV sequences present in the reporter 
plasmid. Therefore, we next sought to determine if the effects 
of pyridoxal phosphate on transcriptional activation were 
restricted to or mediated specifically through  the hormonally 
regulated MMTV promoter. To this  end, we examined tran- 
scriptional activation mediated by a different steroid receptor, 
the estrogen receptor, which acts through a distinct DNA 
sequence (65, 66). This sequence, the estrogen-response ele- 
ment, is associated with estrogen-regulated genes and me- 
diates effects of the estrogen receptor specifically (42). In 
particular, we have used a well-characterized fragment from 
the estrogen-inducible vitellogenin gene promoter (42) to 
direct expression of the  reporter CAT gene. 
HeLa cells are devoid of endogenous estrogen receptors, but 
express functional receptors and exhibit estrogen-responsive 
transcriptional activation after  transfection with an estrogen 
receptor expression vector (40, 67-69). Since we have previ- 
ously characterized in these cells the effects on intracellular 
pyridoxal phosphate concentration that arise from supple- 
mentation of the culture medium with synthesis precursors 
or inhibitors  (36), we chose to use these cells as  the exper- 
imental model for examination of vitamin effects on estro- 
gen receptor-mediated transcription. For these studies, cells 
were transfected with both an expression vector that directs 
production of functional human estrogen receptor, pHEO, 
and  the  strogen-responsive  CAT  reporter  plasmid 
pERENF1CAT. After transfection, cells were  exposed to  the 
concentrations of pyridoxine or 4-deoxypyridoxine which we 
have shown alter  intracellular pyridoxal phosphate concen- 
tration  and modulate glucocorticoid receptor-mediated induc- 
tion of transcription (Ref. 36 and Fig. 1). Results from these 
experiments, presented  in Fig. 4, demonstrated that estrogen- 
induced CAT activity was suppressed by 30% under pyridox- 
ine conditions that elevate intracellular pyridoxal phosphate 
concentration, while mild vitamin deficiency resulted in an 
85%  enhancement in the level of estrogen-induced CAT ac- 
tivity. Thus,  the effects of vitamin concentration on estrogen 
receptor-mediated transcriptional activation were analogous 
to those which we had previously  observed with the glucocor- 
ticoid receptor endogenously present in these same cells, as 
demonstrated  in Fig. 1. Another significant point to be made 
from this series of experiments is that modulation of receptor- 













FIG. 4. Estrogen receptor-mediated gene expression is mod- 
ulated by alterations in intracellular pyridoxal phosphate 
concentration. HeLa cells were transfected  with  the  estrogen recep- 
tor expression  vector pHEO  and  the  estrogen-regulated CAT reporter 
pERENF1CAT.  Sixteen  hours  after  transfection, cells were exposed 
to  control medium ( C O N ) ,  medium supplemented with 1 mM pyri- 
doxine ( P Y R ) ,  or medium supplemented  with 5 mM 4-deoxypyridox- 
ine ( 4 D X Y )  prior to  a 24-h treatment with 5 nM 176-estradiol or 
vehicle and CAT activity determination. The data shown reflect 
results from at least  three individual transfection  experiments. 
induced gene expression was not restricted to the MMTV 
promoter.  This  finding  supports  the  hypothesis  that  altera- 
tions in intracellular vitamin Bs concentration can affect 
transcription  mediated  through  other  hormonally  regulated 
promoters. 
DISCUSSION 
The  first suggestion that glucocorticoid receptor function 
was  influenced by vitamin Bs was  derived from  early  studies 
in which it was  shown that  modulation of vitamin Bs concen- 
tration  in  cultured cells or  tissue  explants  affects  the l vels of 
glucocorticoid-induced tyrosine  aminotransferase (70) and  al- 
kaline  phosphatase  enzymatic  activities (71), as well as casein 
mRNA (72). Moreover, gestational pyridoxine administration 
was  demonstrated  to reduce the incidence of glucocorticoid- 
induced cleft palate  formation  in  rats (73). It  is  clear from the 
studies described in Figs. 1 and 2 that the transcriptional 
activation  capacity of the glucocorticoid receptor  is influenced 
by vitamin B6 concentration.  This  modulatory effect is ob- 
served  in diverse  cell types and  with glucocorticoid receptor 
of different species. I t  is quite likely, then,  that  vitamin Bs 
influences glucocorticoid receptor-mediated  transcription of 
the tyrosine  aminotransferase,  alkaline  phosphatase,  and  cas- 
ein genes. A clear  mechanism  is  not so apparent  in  the cleft 
palate  study. However, glucocorticoid receptor-mediated gene 
expression  is  undoubtedly a fundamental  component  in  the 
process of hormone-induced cleft palate  formation,  and  our 
studies  indicate  that  vitamin Bs would also  act  to affect this 
process at  the level of modulation of hormone-induced gene 
expression. 
From  the  studies hown in Figs. 3 and 4, it  is  apparent  that 
alterations in vitamin concentration analogously affect the 
transcriptional  activation  capacities of other  steroid  hormone 
receptors, suggesting that  the  vitamin may act at the  tran- 
scriptional level to  modulate  steroid  hormone  action  in gen- 
eral, and not just glucocorticoid hormone action. This hy- 
pothesis is supported by the observations of vitamin Bs- 
induced alterations  in  the level of estrogen-induced  uterine 
growth  and peroxidase activity (34), as well as  the  enhance- 
ment in androgen-mediated  prostate growth  observed in vi- 
tamin deficiency (33). 
It is important to note that these different hormonally 
regulated  genes (tyrosine  aminotransferase,  alkaline  phospha- 
tase,  and casein), with  different  promoters,  are  similarly  af- 
fected by modulation of vitamin  concentration:  in  all  cases 
where it has been examined, hormone response is reduced 
under  conditions of elevated vitamin  concentration  and  en- 
hanced  under  conditions of vitamin deficiency. This  consist- 
ent modulatory response is also observed in  the  studies  on 
the  hormone-regulated physiological processes of uterine  and 
prostate growth (33,  34). The  data  presented  in Fig. 4 dem- 
onstrate  that  vitamin  concentration  modulates gene expres- 
sion mediated through different hormonally regulated pro- 
moters,  and we conclude that  vitamin Bs acts  at  the level of 
receptor-mediated  transcriptional  activation  to modulate the 
biological actions of different  steroid  hormone receptors. 
The  data  presented  in  this  report  are  consistent with the 
idea that  the  transcriptional modulatory  effects of the  vitamin 
are  mediated  through  the receptor molecules themselves. 
There is a preponderance of evidence suggesting a direct 
interaction of pyridoxal phosphate with the glucocorticoid 
receptor, including interaction of the receptor with  an  anti- 
body directed  against pyridoxal phosphate (60), and  preven- 
tion of receptor cleavage with exogenously applied trypsin by 
prior exposure to pyridoxal phosphate (2). In  its classical role 
as a cofactor in  many  enzymatic  reactions, pyridoxal phos- 
phate  interacts  with specific amino acids, predominantly ly- 
sine residues (74). Thus,  it is possible that pyridoxal phos- 
phate also interacts  with  the glucocorticoid receptor through 
a similar association with specific amino acids, potentially 
lysines. If this is, in  fact,  the  mechanism  through which the 
transcriptional  modulatory effects of the  vitamin  are 
achieved, then it follows that pyridoxal phosphate would also 
interact  with  the  estrogen,  androgen,  and progesterone  recep- 
tors.  In  fact,  with  the  significant degree of sequence homology 
which exists between these  proteins,  there may be a consensus 
sequence or region common to  these four receptors  with which 
pyridoxal phosphate  interacts  to  mediate  its effects on  tran- 
scriptional  activation.  Mutational  analysis will determine if 
there exists a binding site for pyridoxal phosphate on the 
glucocorticoid receptor,  as evidence in  the  literature suggests. 
Further  studies will then  be necessary to  evaluate  the possi- 
bility of a common  site  among  other members of the highly 
conserved steroid  hormone receptor  superfamily which allows 
modulation of gene expression by alterations  in  intracellular 
vitamin Bs concentration. 
In conclusion, the  studies described here  demonstrate  that 
pyridoxal phosphate  concentration  affects  the level of gluco- 
corticoid receptor-induced gene expression without  depend- 
ence  on  receptor species or cell type. In  addition,  transcrip- 
tional  activation by other  steroid  hormone  receptors  is  anal- 
ogously modulated,  and  is observed  with different hormonally 
regulated promoters.  These  observations  together  are  impor- 
tant when considering  the  concept of regulation of hormone 
action: a regulator, or regulatory mechanism, would be re- 
quired  to affect multiple  hormone  receptors similarly, func- 
tioning  in a variety of cell types to modulate  the expression 
of a  diverse  group of target genes. It  is  clear  that  vitamin Bs 
acts  through a  specific mechanism,  modulation of transcrip- 
tional  activation,  to regulate the physiological actions of mul- 
tiple members of the  steroid  hormone receptor  superfamily. 
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